Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224651 | 0.89 | MEN1 (1.00) | MEN1KMT2AL3MBTL1TP53TSHR | |
| SCHEMBL224471 | 0.89 | MEN1 (1.00) | MEN1KMT2AL3MBTL1TP53TSHR | |
| SCHEMBL1531929 | 0.89 | MEN1 (1.00) | MEN1KMT2AL3MBTL1TP53TSHR | |
| SCHEMBL15478773 | 0.88 | MEN1 (0.80) | MEN1KMT2AHRH3KDM4CGAA | |
| SCHEMBL12768363 | 0.86 | KMT2A (0.78) | MEN1KMT2AHRH3KDM4CGAA | |
| SCHEMBL1531938 | 0.86 | KMT2A (0.78) | MEN1KMT2AHRH3KDM4CGAA | |
| SCHEMBL9335079 | 0.86 | MEN1 (0.95) | MEN1KMT2AHRH3L3MBTL1TP53 | |
| SCHEMBL12768508 | 0.85 | MEN1 (0.76) | MEN1KMT2AHRH3GAANPC1 | |
| SCHEMBL28597015 | 0.85 | MEN1 (0.93) | MEN1KMT2ATP53TSHR | |
| SCHEMBL1531787 | 0.85 | MEN1 (0.76) | MEN1KMT2AHRH3GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2698412-A2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-7910019-B2 | Mesogen containing compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | MEN1 117/4885KMT2A 3837/4885HRH3 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.